Non-Classical Effects of FGF23: Molecular and Clinical Features
Abstract
:1. Introduction
2. FGF23 Effects over Vitamin D, PTH, and Bone Metabolism
2.1. Vitamin D
2.2. PTH
2.3. Bone Metabolism
3. Cardiovascular Effects
3.1. Endothelial Dysfunction
3.2. Left Ventricular Hypertrophy
3.3. Cardiac Fibrosis
3.4. FGF23 and the Renin–Angiotensin–Aldosterone System
3.5. Atherosclerosis
4. FGF23 and Iron Metabolism
4.1. Iron Deficiency
4.2. Hypoxia
4.3. Erythropoietin (EPO)
4.4. Iron Repletion
5. FGF23 and Renal Failure
6. Inflammation and Immune System
7. FGF23 and Obesity
8. FGF 23 as a Biomarker
9. FGF23 as a Therapeutic Target
10. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Château, M.-T.; Araiz, C.; Descamps, S.; Galas, S. Klotho Interferes with a Novel FGF-Signalling Pathway and Insulin/Igf-like Signalling to Improve Longevity and Stress Resistance in Caenorhabditis Elegans. Aging 2010, 2, 567–581. [Google Scholar] [CrossRef]
- Li, D.-J.; Fu, H.; Zhao, T.; Ni, M.; Shen, F.-M. Exercise-Stimulated FGF23 Promotes Exercise Performance via Controlling the Excess Reactive Oxygen Species Production and Enhancing Mitochondrial Function in Skeletal Muscle. Metab.—Clin. Exp. 2016, 65, 747–756. [Google Scholar] [CrossRef]
- Agoro, R.; White, K.E. Regulation of FGF23 Production and Phosphate Metabolism by Bone–Kidney Interactions. Nat. Rev. Nephrol. 2023, 19, 185–193. [Google Scholar] [CrossRef] [PubMed]
- Wasserman, H.; Ikomi, C.; Hafberg, E.T.; Miethke, A.G.; Bove, K.E.; Backeljauw, P.F. Two Case Reports of FGF23-Induced Hypophosphatemia in Childhood Biliary Atresia. Pediatrics 2016, 138, e20154453. [Google Scholar] [CrossRef] [PubMed]
- Ursem, S.R.; Diepenbroek, C.; Bacic, V.; Unmehopa, U.A.; Eggels, L.; Maya-Monteiro, C.M.; Heijboer, A.C.; la Fleur, S.E. Localization of Fibroblast Growth Factor 23 Protein in the Rat Hypothalamus. Eur. J. Neurosci. 2021, 54, 5261–5271. [Google Scholar] [CrossRef] [PubMed]
- Matsui, I.; Oka, T.; Kusunoki, Y.; Mori, D.; Hashimoto, N.; Matsumoto, A.; Shimada, K.; Yamaguchi, S.; Kubota, K.; Yonemoto, S.; et al. Cardiac Hypertrophy Elevates Serum Levels of Fibroblast Growth Factor 23. Kidney Int. 2018, 94, 60–71. [Google Scholar] [CrossRef] [PubMed]
- Lin, C.-H.; Chang, C.-K.; Shih, C.-W.; Li, H.-Y.; Chen, K.-Y.; Yang, W.-S.; Tsai, K.-S.; Wang, C.-Y.; Shih, S.-R. Serum Fibroblast Growth Factor 23 and Mineral Metabolism in Patients with Euthyroid Graves’ Diseases: A Case-Control Study. Osteoporos. Int. 2019, 30, 2289–2297. [Google Scholar] [CrossRef]
- Onal, M.; Carlson, A.H.; Thostenson, J.D.; Benkusky, N.A.; Meyer, M.B.; Lee, S.M.; Pike, J.W. A Novel Distal Enhancer Mediates Inflammation-, PTH-, and Early Onset Murine Kidney Disease-Induced Expression of the Mouse Fgf23 Gene. JBMR Plus 2018, 2, 31–46. [Google Scholar] [CrossRef] [PubMed]
- Si, Y.; Kazamel, M.; Benatar, M.; Wuu, J.; Kwon, Y.; Kwan, T.; Jiang, N.; Kentrup, D.; Faul, C.; Alesce, L.; et al. FGF23, a Novel Muscle Biomarker Detected in the Early Stages of ALS. Sci. Rep. 2021, 11, 12062. [Google Scholar] [CrossRef]
- Hu, M.C.; Shi, M.; Moe, O.W. Role of αKlotho and FGF23 in Regulation of Type II Na-Dependent Phosphate Co-Transporters. Pflüg. Arch.—Eur. J. Physiol. 2019, 471, 99–108. [Google Scholar] [CrossRef]
- Latic, N.; Erben, R.G. Interaction of Vitamin D with Peptide Hormones with Emphasis on Parathyroid Hormone, FGF23, and the Renin-Angiotensin-Aldosterone System. Nutrients 2022, 14, 5186. [Google Scholar] [CrossRef] [PubMed]
- Smith, E.R.; Holt, S.G.; Hewitson, T.D. αKlotho–FGF23 Interactions and Their Role in Kidney Disease: A Molecular Insight. Cell. Mol. Life Sci. 2019, 76, 4705–4724. [Google Scholar] [CrossRef]
- D’Arrigo, G.; Pizzini, P.; Cutrupi, S.; Tripepi, R.; Tripepi, G.; Mallamaci, F.; Zoccali, C. FGF23 and the PTH Response to Paricalcitol in Chronic Kidney Disease. Eur. J. Clin. Investig. 2020, 50, e13196. [Google Scholar] [CrossRef] [PubMed]
- Stathi, D.; Fountoulakis, N.; Panagiotou, A.; Maltese, G.; Corcillo, A.; Mangelis, A.; Ayis, S.; Gnudi, L.; Karalliedde, J. Impact of Treatment with Active Vitamin D Calcitriol on Bone Turnover Markers in People with Type 2 Diabetes and Stage 3 Chronic Kidney Disease. Bone 2023, 166, 116581. [Google Scholar] [CrossRef] [PubMed]
- Isakova, T.; Cai, X.; Lee, J.; Katz, R.; Cauley, J.A.; Fried, L.F.; Hoofnagle, A.N.; Satterfield, S.; Harris, T.B.; Shlipak, M.G.; et al. Associations of FGF23 with Change in Bone Mineral Density and Fracture Risk in Older Individuals. J. Bone Miner. Res. 2016, 31, 742–748. [Google Scholar] [CrossRef] [PubMed]
- Chua, W.; Cardoso, V.R.; Guasch, E.; Sinner, M.F.; Al-Taie, C.; Brady, P.; Casadei, B.; Crijns, H.J.G.M.; Dudink, E.A.M.P.; Hatem, S.N.; et al. An Angiopoietin 2, FGF23, and BMP10 Biomarker Signature Differentiates Atrial Fibrillation from Other Concomitant Cardiovascular Conditions. Sci. Rep. 2023, 13, 16743. [Google Scholar] [CrossRef] [PubMed]
- Donovan, K.; Herrington, W.G.; Paré, G.; Pigeyre, M.; Haynes, R.; Sardell, R.; Butterworth, A.S.; Folkersen, L.; Gustafsson, S.; Wang, Q.; et al. Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases. Clin. J. Am. Soc. Nephrol. CJASN 2023, 18, 17–27. [Google Scholar] [CrossRef] [PubMed]
- Edmonston, D.; Wolf, M. FGF23 at the Crossroads of Phosphate, Iron Economy and Erythropoiesis. Nat. Rev. Nephrol. 2020, 16, 7–19. [Google Scholar] [CrossRef]
- Gan, X.; Guo, M.; Chen, Z.; Li, Y.; Shen, F.; Feng, J.; Cai, W.; Xu, B. Development and Validation of a Three-Immune-Related Gene Signature Prognostic Risk Model in Papillary Thyroid Carcinoma. J. Endocrinol. Investig. 2021, 44, 2153–2163. [Google Scholar] [CrossRef]
- van der Vaart, A.; Eelderink, C.; van Beek, A.P.; Bakker, S.J.L.; van Dijk, P.R.; de Borst, M.H. Fibroblast Growth Factor 23, Glucose Homeostasis, and Incident Diabetes: Findings of 2 Cohort Studies. J. Clin. Endocrinol. Metab. 2023, 108, e971–e978. [Google Scholar] [CrossRef]
- Ranch, D.; Zhang, M.Y.; Portale, A.A.; Perwad, F. Fibroblast Growth Factor 23 Regulates Renal 1,25-Dihydroxyvitamin D and Phosphate Metabolism via the MAP Kinase Signaling Pathway in Hyp Mice. J. Bone Miner. Res. 2011, 26, 1883–1890. [Google Scholar] [CrossRef]
- DeLuca, S.; Sitara, D.; Kang, K.; Marsell, R.; Jonsson, K.; Taguchi, T.; Erben, R.; Razzaque, M.; Lanske, B. Amelioration of the Premature Ageing-like Features of Fgf-23 Knockout Mice by Genetically Restoring the Systemic Actions of FGF-23. J. Pathol. 2008, 216, 345–355. [Google Scholar] [CrossRef]
- Niemann, K.E.; Kröpil, F.; Hoffmann, M.F.; Coulibaly, M.O.; Schildhauer, T.A. A 23-Year-Old Patient with Secondary Tumoral Calcinosis: Regression after Subtotal Parathyroidectomy: A Case Report. Int. J. Surg. Case Rep. 2016, 23, 56–60. [Google Scholar] [CrossRef]
- Gowda, V.K.; Raj, A.; Vamyanmane, D.K.; Nagarajappa, V.H.; Srinivas, S.M.; Tirumale, R.; Ranganath, J.; Gaddehosur, C.; Vishwanathan, G.B. Recurrent Bilateral Lower Motor Neuron Type of Facial Palsy with Hearing Impairment: Hyperphosphatemic Familial Tumoral Calcinosis. J. Pediatr. Genet. 2023, 12, 280–287. [Google Scholar] [CrossRef]
- Kägi, L.; Bettoni, C.; Pastor-Arroyo, E.M.; Schnitzbauer, U.; Hernando, N.; Wagner, C.A. Regulation of Vitamin D Metabolizing Enzymes in Murine Renal and Extrarenal Tissues by Dietary Phosphate, FGF23, and 1,25(OH)2D3. PLoS ONE 2018, 13, e0195427. [Google Scholar] [CrossRef]
- Spoto, B.; Pizzini, P.; Tripepi, G.; Mallamaci, F.; Zoccali, C. Circulating Adiponectin Modifies the FGF23 Response to Vitamin D Receptor Activation: A Post Hoc Analysis of a Double-Blind, Randomized Clinical Trial. Nephrol. Dial. Transplant. 2018, 33, 1764–1769. [Google Scholar] [CrossRef]
- Xie, H.; Bastepe, I.; Zhou, W.; Ay, B.; Ceraj, Z.; Portales-Castillo, I.A.; Liu, E.S.; Burnett-Bowie, S.-A.M.; Jüppner, H.; Rhee, E.P.; et al. 1,25-Dihydroxyvitamin D3 Regulates Furin-Mediated FGF23 Cleavage. JCI Insight 2023, 8, e168957. [Google Scholar] [CrossRef]
- Nguyen-Yamamoto, L.; Karaplis, A.C.; St–Arnaud, R.; Goltzman, D. Fibroblast Growth Factor 23 Regulation by Systemic and Local Osteoblast-Synthesized 1,25-Dihydroxyvitamin D. J. Am. Soc. Nephrol. JASN 2017, 28, 586–597. [Google Scholar] [CrossRef]
- Investigating the Effect of Paricalcitol on Serum FGF23 in Vitamin D Deficient Rats. Available online: https://www.researchsquare.com (accessed on 22 January 2024).
- Zittermann, A.; Berthold, H.K.; Pilz, S. The Effect of Vitamin D on Fibroblast Growth Factor 23: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Eur. J. Clin. Nutr. 2021, 75, 980–987. [Google Scholar] [CrossRef]
- Meshkini, F.; Soltani, S.; Clark, C.C.T.; Tam, V.; Meyre, D.; Toupchian, O.; Saraf-Bank, S.; Abdollahi, S. The Effect of Vitamin D Supplementation on Serum Levels of Fibroblast Growth Factor-23: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Steroid Biochem. Mol. Biol. 2022, 215, 106012. [Google Scholar] [CrossRef]
- Razzaque, M.S. Interactions between FGF23 and Vitamin D. Endocr. Connect. 2022, 11, e220239. Available online: https://ec.bioscientifica.com/view/journals/ec/11/10/EC-22-0239.xml (accessed on 22 January 2024). [CrossRef] [PubMed]
- Zeng, S.; Querfeld, U.; Feger, M.; Haffner, D.; Hasan, A.A.; Chu, C.; Slowinski, T.; Bernd Dschietzig, T.; Schäfer, F.; Xiong, Y.; et al. Relationship between GFR, Intact PTH, Oxidized PTH, Non-Oxidized PTH as Well as FGF23 in Patients with CKD. FASEB J. 2020, 34, 15269–15281. [Google Scholar] [CrossRef]
- Aniteli, T.M.; de Siqueira, F.R.; dos Reis, L.M.; Dominguez, W.V.; de Oliveira, E.M.C.; Castelucci, P.; Moysés, R.M.A.; Jorgetti, V. Effect of Variations in Dietary Pi Intake on Intestinal Pi Transporters (NaPi-IIb, PiT-1, and PiT-2) and Phosphate-Regulating Factors (PTH, FGF-23, and MEPE). Pflüg. Arch.—Eur. J. Physiol. 2018, 470, 623–632. [Google Scholar] [CrossRef]
- Rhee, Y.; Bivi, N.; Farrow, E.; Lezcano, V.; Plotkin, L.I.; White, K.E.; Bellido, T. Parathyroid Hormone Receptor Signaling in Osteocytes Increases the Expression of Fibroblast Growth Factor-23 in Vitro and in Vivo. Bone 2011, 49, 636–643. [Google Scholar] [CrossRef]
- Mace, M.L.; Gravesen, E.; Nordholm, A.; Olgaard, K.; Lewin, E. Fibroblast Growth Factor (FGF) 23 Regulates the Plasma Levels of Parathyroid Hormone In Vivo through the FGF Receptor in Normocalcemia, But Not in Hypocalcemia. Calcif. Tissue Int. 2018, 102, 85–92. [Google Scholar] [CrossRef]
- Grabner, A.; Amaral, A.P.; Schramm, K.; Singh, S.; Sloan, A.; Yanucil, C.; Li, J.; Shehadeh, L.A.; Hare, J.M.; David, V.; et al. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab. 2015, 22, 1020–1032. [Google Scholar] [CrossRef]
- Isakova, T.; Wahl, P.; Vargas, G.S.; Gutiérrez, O.M.; Scialla, J.; Xie, H.; Appleby, D.; Nessel, L.; Bellovich, K.; Chen, J.; et al. Fibroblast Growth Factor 23 Is Elevated before Parathyroid Hormone and Phosphate in Chronic Kidney Disease. Kidney Int. 2011, 79, 1370–1378. [Google Scholar] [CrossRef]
- Lavi-Moshayoff, V.; Wasserman, G.; Meir, T.; Silver, J.; Naveh-Many, T. PTH Increases FGF23 Gene Expression and Mediates the High-FGF23 Levels of Experimental Kidney Failure: A Bone Parathyroid Feedback Loop. Am. J. Physiol.-Ren. Physiol. 2010, 299, F882–F889. [Google Scholar] [CrossRef]
- López, I.; Rodríguez-Ortiz, M.E.; Almadén, Y.; Guerrero, F.; de Oca, A.M.; Pineda, C.; Shalhoub, V.; Rodríguez, M.; Aguilera-Tejero, E. Direct and Indirect Effects of Parathyroid Hormone on Circulating Levels of Fibroblast Growth Factor 23 In Vivo. Kidney Int. 2011, 80, 475–482. [Google Scholar] [CrossRef] [PubMed]
- Samadfam, R.; Richard, C.; Nguyen-Yamamoto, L.; Bolivar, I.; Goltzman, D. Bone Formation Regulates Circulating Concentrations of Fibroblast Growth Factor 23. Endocrinology 2009, 150, 4835–4845. [Google Scholar] [CrossRef] [PubMed]
- Saji, F.; Shiizaki, K.; Shimada, S.; Okada, T.; Kunimoto, K.; Sakaguchi, T.; Hatamura, I.; Shigematsu, T. Regulation of Fibroblast Growth Factor 23 Production in Bone in Uremic Rats. Nephron Physiol. 2009, 111, 61–68. [Google Scholar] [CrossRef]
- Kamelian, T.; Saki, F.; Jeddi, M.; Dabbaghmanesh, M.H.; Omrani, G.H.R. Effect of Cholecalciferol Therapy on Serum FGF23 in Vitamin D Deficient Patients: A Randomized Clinical Trial. J. Endocrinol. Investig. 2018, 41, 299–306. [Google Scholar] [CrossRef]
- Saki, F.; Kassaee, S.R.; Salehifar, A.; Omrani, G.H.R. Interaction between Serum FGF-23 and PTH in Renal Phosphate Excretion, a Case-Control Study in Hypoparathyroid Patients. BMC Nephrol. 2020, 21, 176. [Google Scholar] [CrossRef]
- Murali, S.K.; Roschger, P.; Zeitz, U.; Klaushofer, K.; Andrukhova, O.; Erben, R.G. FGF23 Regulates Bone Mineralization in a 1,25(OH)2D3 and Klotho-Independent Manner. J. Bone Miner. Res. 2016, 31, 129–142. [Google Scholar] [CrossRef]
- Shalhoub, V.; Ward, S.C.; Sun, B.; Stevens, J.; Renshaw, L.; Hawkins, N.; Richards, W.G. Fibroblast Growth Factor 23 (FGF23) and Alpha-Klotho Stimulate Osteoblastic MC3T3.E1 Cell Proliferation and Inhibit Mineralization. Calcif. Tissue Int. 2011, 89, 140–150. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Yoshiko, Y.; Yamamoto, R.; Minamizaki, T.; Kozai, K.; Tanne, K.; Aubin, J.E.; Maeda, N. Overexpression of Fibroblast Growth Factor 23 Suppresses Osteoblast Differentiation and Matrix Mineralization In Vitro*. J. Bone Miner. Res. 2008, 23, 939–948. [Google Scholar] [CrossRef]
- Carrillo-López, N.; Panizo, S.; Alonso-Montes, C.; Román-García, P.; Rodríguez, I.; Martínez-Salgado, C.; Dusso, A.S.; Naves, M.; Cannata-Andía, J.B. Direct Inhibition of Osteoblastic Wnt Pathway by Fibroblast Growth Factor 23 Contributes to Bone Loss in Chronic Kidney Disease. Kidney Int. 2016, 90, 77–89. [Google Scholar] [CrossRef]
- Sirikul, W.; Siri-Angkul, N.; Chattipakorn, N.; Chattipakorn, S.C. Fibroblast Growth Factor 23 and Osteoporosis: Evidence from Bench to Bedside. Int. J. Mol. Sci. 2022, 23, 2500. [Google Scholar] [CrossRef]
- Li, Y.; He, X.; Olauson, H.; Larsson, T.E.; Lindgren, U. FGF23 Affects the Lineage Fate Determination of Mesenchymal Stem Cells. Calcif. Tissue Int. 2013, 93, 556–564. [Google Scholar] [CrossRef]
- Anderson, P.H. Vitamin D Activity and Metabolism in Bone. Curr. Osteoporos. Rep. 2017, 15, 443–449. [Google Scholar] [CrossRef]
- Allard, L.; Demoncheaux, N.; Machuca-Gayet, I.; Georgess, D.; Coury-Lucas, F.; Jurdic, P.; Bacchetta, J. Biphasic Effects of Vitamin D and FGF23 on Human Osteoclast Biology. Calcif. Tissue Int. 2015, 97, 69–79. [Google Scholar] [CrossRef]
- Marsell, R.; Mirza, M.A.I.; Mallmin, H.; Karlsson, M.; Mellström, D.; Orwoll, E.; Ohlsson, C.; Jonsson, K.B.; Ljunggren, Ö.; Larsson, T.E. Relation between Fibroblast Growth Factor-23, Body Weight and Bone Mineral Density in Elderly Men. Osteoporos. Int. 2009, 20, 1167–1173. [Google Scholar] [CrossRef]
- Lane, N.E.; Parimi, N.; Corr, M.; Yao, W.; Cauley, J.A.; Nielson, C.M.; Ix, J.; Kado, D.; Orwoll, E. Association of Serum Fibroblast Growth Factor 23 (FGF23) and Incident Fractures in Older Men: The Osteoporotic Fractures in Men (MrOS) Study. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2013, 28, 2325–2332. [Google Scholar] [CrossRef]
- Shen, J.; Fu, S.; Song, Y. Relationship of Fibroblast Growth Factor 23 (FGF-23) Serum Levels With Low Bone Mass in Postmenopausal Women. J. Cell. Biochem. 2017, 118, 4454–4459. [Google Scholar] [CrossRef]
- Bilha, S.C.; Bilha, A.; Ungureanu, M.-C.; Matei, A.; Florescu, A.; Preda, C.; Covic, A.; Branisteanu, D. FGF23 Beyond the Kidney: A New Bone Mass Regulator in the General Population. Horm. Metab. Res. 2020, 52, 298–304. [Google Scholar] [CrossRef]
- Rupp, T.; Butscheidt, S.; Vettorazzi, E.; Oheim, R.; Barvencik, F.; Amling, M.; Rolvien, T. High FGF23 Levels Are Associated with Impaired Trabecular Bone Microarchitecture in Patients with Osteoporosis. Osteoporos. Int. 2019, 30, 1655–1662. [Google Scholar] [CrossRef]
- Mirza, M.A.; Karlsson, M.K.; Mellström, D.; Orwoll, E.; Ohlsson, C.; Ljunggren, Ö.; Larsson, T.E. Serum Fibroblast Growth Factor-23 (FGF-23) and Fracture Risk in Elderly Men. J. Bone Miner. Res. 2011, 26, 857–864. [Google Scholar] [CrossRef]
- Desbiens, L.-C.; Sidibé, A.; Ung, R.-V.; Mac-Way, F. FGF23-Klotho Axis and Fractures in Patients without and with Early CKD: A Case-Cohort Analysis of CARTaGENE. J. Clin. Endocrinol. Metab. 2022, 107, e2502–e2512. [Google Scholar] [CrossRef]
- Kanda, E.; Yoshida, M.; Sasaki, S. Applicability of Fibroblast Growth Factor 23 for Evaluation of Risk of Vertebral Fracture and Chronic Kidney Disease-Mineral Bone Disease in Elderly Chronic Kidney Disease Patients. BMC Nephrol. 2012, 13, 122. [Google Scholar] [CrossRef] [PubMed]
- Andrukhova, O.; Schüler, C.; Bergow, C.; Petric, A.; Erben, R.G. Augmented Fibroblast Growth Factor-23 Secretion in Bone Locally Contributes to Impaired Bone Mineralization in Chronic Kidney Disease in Mice. Front. Endocrinol. 2018, 9, 311. [Google Scholar] [CrossRef] [PubMed]
- Shalhoub, V.; Shatzen, E.M.; Ward, S.C.; Davis, J.; Stevens, J.; Bi, V.; Renshaw, L.; Hawkins, N.; Wang, W.; Chen, C.; et al. FGF23 Neutralization Improves Chronic Kidney Disease–Associated Hyperparathyroidism yet Increases Mortality. J. Clin. Investig. 2012, 122, 2543–2553. [Google Scholar] [CrossRef]
- Sun, N.; Guo, Y.; Liu, W.; Densmore, M.; Shalhoub, V.; Erben, R.G.; Ye, L.; Lanske, B.; Yuan, Q. FGF23 Neutralization Improves Bone Quality and Osseointegration of Titanium Implants in Chronic Kidney Disease Mice. Sci. Rep. 2015, 5, 8304. [Google Scholar] [CrossRef]
- Ärnlöv, J.; Carlsson, A.C.; Sundström, J.; Ingelsson, E.; Larsson, A.; Lind, L.; Larsson, T.E. Higher Fibroblast Growth Factor-23 Increases the Risk of All-Cause and Cardiovascular Mortality in the Community. Kidney Int. 2013, 83, 160–166. [Google Scholar] [CrossRef]
- Baia, L.C.; Humalda, J.K.; Vervloet, M.G.; Navis, G.; Bakker, S.J.L.; de Borst, M.H. Fibroblast Growth Factor 23 and Cardiovascular Mortality after Kidney Transplantation. Clin. J. Am. Soc. Nephrol. 2013, 8, 1968. [Google Scholar] [CrossRef]
- Liu, M.; Xia, P.; Tan, Z.; Song, T.; Mei, K.; Wang, J.; Ma, J.; Jiang, Y.; Zhang, J.; Zhao, Y.; et al. Fibroblast Growth Factor-23 and the Risk of Cardiovascular Diseases and Mortality in the General Population: A Systematic Review and Dose-Response Meta-Analysis. Front. Cardiovasc. Med. 2022, 9, 989574. [Google Scholar] [CrossRef] [PubMed]
- Lindberg, K.; Olauson, H.; Amin, R.; Ponnusamy, A.; Goetz, R.; Taylor, R.F.; Mohammadi, M.; Canfield, A.; Kublickiene, K.; Larsson, T.E. Arterial Klotho Expression and FGF23 Effects on Vascular Calcification and Function. PLoS ONE 2013, 8, e60658. [Google Scholar] [CrossRef] [PubMed]
- Yilmaz, M.I.; Sonmez, A.; Saglam, M.; Yaman, H.; Kilic, S.; Demirkaya, E.; Eyileten, T.; Caglar, K.; Oguz, Y.; Vural, A.; et al. FGF-23 and Vascular Dysfunction in Patients with Stage 3 and 4 Chronic Kidney Disease. Kidney Int. 2010, 78, 679–685. [Google Scholar] [CrossRef] [PubMed]
- Mirza, M.A.I.; Larsson, A.; Lind, L.; Larsson, T.E. Circulating Fibroblast Growth Factor-23 Is Associated with Vascular Dysfunction in the Community. Atherosclerosis 2009, 205, 385–390. [Google Scholar] [CrossRef]
- Yilmaz, M.I.; Sonmez, A.; Saglam, M.; Yaman, H.; Kilic, S.; Turker, T.; Unal, H.U.; Gok, M.; Cetinkaya, H.; Eyileten, T.; et al. Longitudinal Analysis of Vascular Function and Biomarkers of Metabolic Bone Disorders before and after Renal Transplantation. Am. J. Nephrol. 2013, 37, 126–134. [Google Scholar] [CrossRef]
- Haffner, D.; Leifheit-Nestler, M. Extrarenal Effects of FGF23. Pediatr. Nephrol. 2017, 32, 753–765. [Google Scholar] [CrossRef]
- Mirza, M.A.I.; Larsson, A.; Melhus, H.; Lind, L.; Larsson, T.E. Serum Intact FGF23 Associate with Left Ventricular Mass, Hypertrophy and Geometry in an Elderly Population. Atherosclerosis 2009, 207, 546–551. [Google Scholar] [CrossRef] [PubMed]
- Faul, C.; Amaral, A.P.; Oskouei, B.; Hu, M.-C.; Sloan, A.; Isakova, T.; Gutiérrez, O.M.; Aguillon-Prada, R.; Lincoln, J.; Hare, J.M.; et al. FGF23 Induces Left Ventricular Hypertrophy. J. Clin. Investig. 2011, 121, 4393–4408. [Google Scholar] [CrossRef] [PubMed]
- Touchberry, C.D.; Green, T.M.; Tchikrizov, V.; Mannix, J.E.; Mao, T.F.; Carney, B.W.; Girgis, M.; Vincent, R.J.; Wetmore, L.A.; Dawn, B.; et al. FGF23 Is a Novel Regulator of Intracellular Calcium and Cardiac Contractility in Addition to Cardiac Hypertrophy. Am. J. Physiol.-Endocrinol. Metab. 2013, 304, E863–E873. [Google Scholar] [CrossRef] [PubMed]
- Unsal, A.; Kose Budak, S.; Koc, Y.; Basturk, T.; Sakaci, T.; Ahbap, E.; Sinangil, A. Relationship of Fibroblast Growth Factor 23 with Left Ventricle Mass Index and Coronary Calcificaton in Chronic Renal Disease. Kidney Blood Press. Res. 2012, 36, 55–64. [Google Scholar] [CrossRef] [PubMed]
- Agarwal, I.; Ide, N.; Ix, J.H.; Kestenbaum, B.; Lanske, B.; Schiller, N.B.; Whooley, M.A.; Mukamal, K.J. Fibroblast Growth Factor–23 and Cardiac Structure and Function. J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis. 2014, 3, e000584. [Google Scholar] [CrossRef] [PubMed]
- Takashi, Y.; Kinoshita, Y.; Hori, M.; Ito, N.; Taguchi, M.; Fukumoto, S. Patients with FGF23-Related Hypophosphatemic Rickets/Osteomalacia Do Not Present with Left Ventricular Hypertrophy. Endocr. Res. 2017, 42, 132–137. [Google Scholar] [CrossRef]
- Liu, E.S.; Thoonen, R.; Petit, E.; Yu, B.; Buys, E.S.; Scherrer-Crosbie, M.; Demay, M.B. Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH. Endocrinology 2018, 159, 2165–2172. [Google Scholar] [CrossRef] [PubMed]
- Pastor-Arroyo, E.-M.; Gehring, N.; Krudewig, C.; Costantino, S.; Bettoni, C.; Knöpfel, T.; Sabrautzki, S.; Lorenz-Depiereux, B.; Pastor, J.; Strom, T.M.; et al. The Elevation of Circulating Fibroblast Growth Factor 23 without Kidney Disease Does Not Increase Cardiovascular Disease Risk. Kidney Int. 2018, 94, 49–59. [Google Scholar] [CrossRef] [PubMed]
- Richter, M.; Lautze, H.-J.; Walther, T.; Braun, T.; Kostin, S.; Kubin, T. The Failing Heart Is a Major Source of Circulating FGF23 via Oncostatin M Receptor Activation. J. Heart Lung Transplant. 2015, 34, 1211–1214. [Google Scholar] [CrossRef]
- Richter, M.; Polyakova, V.; Gajawada, P.; Pöling, J.; Warnecke, H.; Braun, T.; Walther, T.; Kubin, T. Oncostatin M Induces FGF23 Expression in Cardiomyocytes. Clin. Exp. Cardiol. 2013, S9, 1–6. [Google Scholar] [CrossRef]
- Andrukhova, O.; Slavic, S.; Odörfer, K.I.; Erben, R.G. Experimental Myocardial Infarction Upregulates Circulating Fibroblast Growth Factor-23. J. Bone Miner. Res. 2015, 30, 1831–1839. [Google Scholar] [CrossRef] [PubMed]
- Slavic, S.; Ford, K.; Modert, M.; Becirovic, A.; Handschuh, S.; Baierl, A.; Katica, N.; Zeitz, U.; Erben, R.G.; Andrukhova, O. Genetic Ablation of Fgf23 or Klotho Does Not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload. Sci. Rep. 2017, 7, 11298. [Google Scholar] [CrossRef] [PubMed]
- Fuernau, G.; Pöss, J.; Denks, D.; Desch, S.; Heine, G.H.; Eitel, I.; Seiler, S.; de Waha, S.; Ewen, S.; Link, A.; et al. Fibroblast Growth Factor 23 in Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Biomarker Substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) Trial. Crit. Care 2014, 18, 713. [Google Scholar] [CrossRef] [PubMed]
- Miao, H.; Wu, X.-Q.; Zhang, D.-D.; Wang, Y.-N.; Guo, Y.; Li, P.; Xiong, Q.; Zhao, Y.-Y. Deciphering the Cellular Mechanisms Underlying Fibrosis-Associated Diseases and Therapeutic Avenues. Pharmacol. Res. 2021, 163, 105316. [Google Scholar] [CrossRef] [PubMed]
- Hao, H.; Li, X.; Li, Q.; Lin, H.; Chen, Z.; Xie, J.; Xuan, W.; Liao, W.; Bin, J.; Huang, X.; et al. FGF23 Promotes Myocardial Fibrosis in Mice through Activation of β-Catenin. Oncotarget 2016, 7, 64649–64664. [Google Scholar] [CrossRef]
- Kuga, K.; Kusakari, Y.; Uesugi, K.; Semba, K.; Urashima, T.; Akaike, T.; Minamisawa, S. Fibrosis Growth Factor 23 Is a Promoting Factor for Cardiac Fibrosis in the Presence of Transforming Growth Factor-Β1. PLoS ONE 2020, 15, e0231905. [Google Scholar] [CrossRef]
- Leifheit-Nestler, M.; Richter, B.; Basaran, M.; Nespor, J.; Vogt, I.; Alesutan, I.; Voelkl, J.; Lang, F.; Heineke, J.; Krick, S.; et al. Impact of Altered Mineral Metabolism on Pathological Cardiac Remodeling in Elevated Fibroblast Growth Factor 23. Front. Endocrinol. 2018, 9, 333. [Google Scholar] [CrossRef]
- Schumacher, D.; Alampour-Rajabi, S.; Ponomariov, V.; Curaj, A.; Wu, Z.; Staudt, M.; Rusu, M.; Jankowski, V.; Marx, N.; Jankowski, J.; et al. Cardiac FGF23: New Insights into the Role and Function of FGF23 after Acute Myocardial Infarction. Cardiovasc. Pathol. 2019, 40, 47–54. [Google Scholar] [CrossRef]
- Vázquez-Sánchez, S.; Poveda, J.; Navarro-García, J.A.; González-Lafuente, L.; Rodríguez-Sánchez, E.; Ruilope, L.M.; Ruiz-Hurtado, G. An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk. Front. Physiol. 2021, 12, 632260. [Google Scholar] [CrossRef]
- Frieler, R.A.; Mortensen, R.M. Immune Cell and Other Noncardiomyocyte Regulation of Cardiac Hypertrophy and Remodeling. Circulation 2015, 131, 1019–1030. [Google Scholar] [CrossRef]
- Dai, B.; David, V.; Martin, A.; Huang, J.; Li, H.; Jiao, Y.; Gu, W.; Quarles, L.D. A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model. PLoS ONE 2012, 7, e44161. [Google Scholar] [CrossRef]
- Fajol, A.; Chen, H.; Umbach, A.T.; Quarles, L.D.; Lang, H.; Föller, M. Enhanced FGF23 Production in Mice Expressing PI3K-Insensitive GSK3 Is Normalized by β-Blocker Treatment. FASEB J. 2016, 30, 994–1001. [Google Scholar] [CrossRef] [PubMed]
- Kovesdy, C.P.; Quarles, L.D. FGF23 from Bench to Bedside. Am. J. Physiol.—Ren. Physiol. 2016, 310, F1168–F1174. [Google Scholar] [CrossRef] [PubMed]
- Leifheit-Nestler, M.; Haffner, D. Paracrine Effects of FGF23 on the Heart. Front. Endocrinol. 2018, 9, 278. [Google Scholar] [CrossRef]
- Srivaths, P.R.; Goldstein, S.L.; Krishnamurthy, R.; Silverstein, D.M. High Serum Phosphorus and FGF 23 Levels Are Associated with Progression of Coronary Calcifications. Pediatr. Nephrol. 2014, 29, 103–109. [Google Scholar] [CrossRef] [PubMed]
- Nakayama, M.; Kaizu, Y.; Nagata, M.; Ura, Y.; Ikeda, H.; Shimamoto, S.; Kuma, K. Fibroblast Growth Factor 23 Is Associated with Carotid Artery Calcification in Chronic Kidney Disease Patients Not Undergoing Dialysis: A Cross-Sectional Study. BMC Nephrol. 2013, 14, 22. [Google Scholar] [CrossRef]
- Voigt, M.; Fischer, D.-C.; Rimpau, M.; Schareck, W.; Haffner, D. Fibroblast Growth Factor (FGF)-23 and Fetuin-A in Calcified Carotid Atheroma. Histopathology 2010, 56, 775–788. [Google Scholar] [CrossRef]
- van Venrooij, N.A.; Pereira, R.C.; Tintut, Y.; Fishbein, M.C.; Tumber, N.; Demer, L.L.; Salusky, I.B.; Wesseling-Perry, K. FGF23 Protein Expression in Coronary Arteries Is Associated with Impaired Kidney Function. Nephrol. Dial. Transplant. 2014, 29, 1525–1532. [Google Scholar] [CrossRef]
- Scialla, J.J.; Lau, W.L.; Reilly, M.P.; Isakova, T.; Yang, H.-Y.; Crouthamel, M.H.; Chavkin, N.W.; Rahman, M.; Wahl, P.; Amaral, A.P.; et al. Fibroblast Growth Factor 23 Is Not Associated with and Does Not Induce Arterial Calcification. Kidney Int. 2013, 83, 1159–1168. [Google Scholar] [CrossRef]
- Jimbo, R.; Kawakami-Mori, F.; Mu, S.; Hirohama, D.; Majtan, B.; Shimizu, Y.; Yatomi, Y.; Fukumoto, S.; Fujita, T.; Shimosawa, T. Fibroblast Growth Factor 23 Accelerates Phosphate-Induced Vascular Calcification in the Absence of Klotho Deficiency. Kidney Int. 2014, 85, 1103–1111. [Google Scholar] [CrossRef]
- Chen, Y.-X.; Huang, C.; Duan, Z.-B.; Xu, C.-Y.; Chen, Y. Klotho/FGF23 Axis Mediates High Phosphate-Induced Vascular Calcification in Vascular Smooth Muscle Cells via Wnt7b/β-Catenin Pathway. Kaohsiung J. Med. Sci. 2019, 35, 393–400. [Google Scholar] [CrossRef] [PubMed]
- Stubbs, J.R.; Liu, S.; Tang, W.; Zhou, J.; Wang, Y.; Yao, X.; Quarles, L.D. Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice. J. Am. Soc. Nephrol. 2007, 18, 2116. [Google Scholar] [CrossRef] [PubMed]
- Imel, E.A.; Hui, S.L.; Ecibs, M.J. FGF23 Concentrations Vary With Disease Status in Autosomal Dominant Hypophosphatemic Rickets. J. Bone Miner. Res. 2007, 22, 520–526. [Google Scholar] [CrossRef] [PubMed]
- Imel, E.A.; Peacock, M.; Gray, A.K.; Padgett, L.R.; Hui, S.L.; Econs, M.J. Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy Humans. J. Clin. Endocrinol. Metab. 2011, 96, 3541–3549. [Google Scholar] [CrossRef] [PubMed]
- Farrow, E.G.; Yu, X.; Summers, L.J.; Davis, S.I.; Fleet, J.C.; Allen, M.R.; Robling, A.G.; Stayrook, K.R.; Jideonwo, V.; Magers, M.J.; et al. Iron Deficiency Drives an Autosomal Dominant Hypophosphatemic Rickets (ADHR) Phenotype in Fibroblast Growth Factor-23 (Fgf23) Knock-in Mice. Proc. Natl. Acad. Sci. USA 2011, 108, E1146–E1155. [Google Scholar] [CrossRef] [PubMed]
- Wheeler, J.A.; Clinkenbeard, E.L. Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF. Curr. Mol. Biol. Rep. 2019, 5, 8–17. [Google Scholar] [CrossRef] [PubMed]
- Babitt, J.L.; Eisenga, M.F.; Haase, V.H.; Kshirsagar, A.V.; Levin, A.; Locatelli, F.; Małyszko, J.; Swinkels, D.W.; Tarng, D.-C.; Cheung, M.; et al. Controversies in Optimal Anemia Management: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 2021, 99, 1280–1295. [Google Scholar] [CrossRef] [PubMed]
- David, V.; Martin, A.; Isakova, T.; Spaulding, C.; Qi, L.; Ramirez, V.; Zumbrennen-Bullough, K.B.; Sun, C.C.; Lin, H.Y.; Babitt, J.L.; et al. Inflammation and Functional Iron Deficiency Regulate Fibroblast Growth Factor 23 Production. Kidney Int. 2016, 89, 135–146. [Google Scholar] [CrossRef] [PubMed]
- Yamashita, K.; Mizuiri, S.; Nishizawa, Y.; Kenichiro, S.; Doi, S.; Masaki, T. Oral Iron Supplementation with Sodium Ferrous Citrate Reduces the Serum Intact and C-terminal Fibroblast Growth Factor 23 Levels of Maintenance Haemodialysis Patients. Nephrol. Carlton Vic 2017, 22, 947–953. [Google Scholar] [CrossRef]
- Simic, P.; Babitt, J.L. Regulation of FGF23: Beyond Bone. Curr. Osteoporos. Rep. 2021, 19, 563–573. [Google Scholar] [CrossRef]
- Rabadi, S.; Udo, I.; Leaf, D.E.; Waikar, S.S.; Christov, M. Acute Blood Loss Stimulates Fibroblast Growth Factor 23 Production. Am. J. Physiol.-Ren. Physiol. 2018, 314, F132–F139. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Q.; Doucet, M.; Tomlinson, R.E.; Han, X.; Quarles, L.D.; Collins, M.T.; Clemens, T.L. The Hypoxia-Inducible Factor-1α Activates Ectopic Production of Fibroblast Growth Factor 23 in Tumor-Induced Osteomalacia. Bone Res. 2016, 4, 16011. [Google Scholar] [CrossRef] [PubMed]
- Hum, J.M.; Clinkenbeard, E.L.; Ip, C.; Cass, T.A.; Allen, M.; White, K.E. The Metabolic Bone Disease Associated with the Hyp Mutation Is Independent of Osteoblastic HIF1α Expression. Bone Rep. 2017, 6, 38–43. [Google Scholar] [CrossRef] [PubMed]
- Tsiftsoglou, A.S. Erythropoietin (EPO) as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of Multipotent Mesenchymal Stem Cells (MSCs): Implications in Regenerative Medicine. Cells 2021, 10, 2140. [Google Scholar] [CrossRef] [PubMed]
- Kautz, L.; Jung, G.; Valore, E.V.; Rivella, S.; Nemeth, E.; Ganz, T. Identification of Erythroferrone as an Erythroid Regulator of Iron Metabolism. Nat. Genet. 2014, 46, 678–684. [Google Scholar] [CrossRef] [PubMed]
- Clinkenbeard, E.L.; Hanudel, M.R.; Stayrook, K.R.; Appaiah, H.N.; Farrow, E.G.; Cass, T.A.; Summers, L.J.; Ip, C.S.; Hum, J.M.; Thomas, J.C.; et al. Erythropoietin Stimulates Murine and Human Fibroblast Growth Factor-23, Revealing Novel Roles for Bone and Bone Marrow. Haematologica 2017, 102, e427–e430. [Google Scholar] [CrossRef] [PubMed]
- Hanudel, M.R.; Eisenga, M.F.; Rappaport, M.; Chua, K.; Qiao, B.; Jung, G.; Gabayan, V.; Gales, B.; Ramos, G.; de Jong, M.A.; et al. Effects of Erythropoietin on Fibroblast Growth Factor 23 in Mice and Humans. Nephrol. Dial. Transplant. 2019, 34, 2057–2065. [Google Scholar] [CrossRef] [PubMed]
- Roszko, K.L.; Brown, S.; Pang, Y.; Huynh, T.; Zhuang, Z.; Pacak, K.; Collins, M.T. C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients with Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. J. Bone Miner. Res. 2021, 36, 315–321. [Google Scholar] [CrossRef] [PubMed]
- Flamme, I.; Ellinghaus, P.; Urrego, D.; Krüger, T. FGF23 Expression in Rodents Is Directly Induced via Erythropoietin after Inhibition of Hypoxia Inducible Factor Proline Hydroxylase. PLoS ONE 2017, 12, e0186979. [Google Scholar] [CrossRef]
- Toro, L.; Barrientos, V.; León, P.; Rojas, M.; Gonzalez, M.; González-Ibáñez, A.; Illanes, S.; Sugikawa, K.; Abarzúa, N.; Bascuñán, C.; et al. Erythropoietin Induces Bone Marrow and Plasma Fibroblast Growth Factor 23 during Acute Kidney Injury. Kidney Int. 2018, 93, 1131–1141. [Google Scholar] [CrossRef]
- Wolf, M.; Koch, T.A.; Bregman, D.B. Effects of Iron Deficiency Anemia and Its Treatment on Fibroblast Growth Factor 23 and Phosphate Homeostasis in Women. J. Bone Miner. Res. 2013, 28, 1793–1803. [Google Scholar] [CrossRef] [PubMed]
- Wolf, M.; Chertow, G.M.; Macdougall, I.C.; Kaper, R.; Krop, J.; Strauss, W. Randomized Trial of Intravenous Iron-Induced Hypophosphatemia. JCI Insight 2018, 3, e124486. [Google Scholar] [CrossRef] [PubMed]
- Francis, C.; Courbon, G.; Gerber, C.; Neuburg, S.; Wang, X.; Dussold, C.; Capella, M.; Qi, L.; Isakova, T.; Mehta, R.; et al. Ferric Citrate Reduces Fibroblast Growth Factor 23 Levels and Improves Renal and Cardiac Function in a Mouse Model of Chronic Kidney Disease. Kidney Int. 2019, 96, 1346–1358. [Google Scholar] [CrossRef] [PubMed]
- Clinkenbeard, E.L.; Farrow, E.G.; Summers, L.J.; Cass, T.A.; Roberts, J.L.; Bayt, C.A.; Lahm, T.; Albrecht, M.; Allen, M.R.; Peacock, M.; et al. Neonatal Iron Deficiency Causes Abnormal Phosphate Metabolism by Elevating FGF23 in Normal and ADHR Mice. J. Bone Miner. Res. 2014, 29, 361–369. [Google Scholar] [CrossRef] [PubMed]
- Bech, A.P.; Bouma-de Krijger, A.; van Zuilen, A.D.; Bots, M.L.; van den Brand, J.A.J.G.; Blankestijn, P.J.; Wetzels, J.F.M.; Vervloet, M.G. Impact of Fractional Phosphate Excretion on the Relation of FGF23 with Outcome in CKD Patients. J. Nephrol. 2015, 28, 477–484. [Google Scholar] [CrossRef] [PubMed]
- Smith, E.R.; Ford, M.L.; Tomlinson, L.A.; McMahon, L.P.; Rajkumar, C.; Holt, S.G. FGF23 Adds Value to Risk Prediction in Patients with Chronic Kidney Disease. Bone 2012, 51, 830–831. [Google Scholar] [CrossRef] [PubMed]
- Titan, S.M.; Zatz, R.; Graciolli, F.G.; dos Reis, L.M.; Barros, R.T.; Jorgetti, V.; Moysés, R.M.A. FGF-23 as a Predictor of Renal Outcome in Diabetic Nephropathy. Clin. J. Am. Soc. Nephrol. 2011, 6, 241. [Google Scholar] [CrossRef] [PubMed]
- Fliser, D.; Kollerits, B.; Neyer, U.; Ankerst, D.P.; Lhotta, K.; Lingenhel, A.; Ritz, E.; Kronenberg, F. Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 2007, 18, 2600. [Google Scholar] [CrossRef] [PubMed]
- Smith, E.R.; Cai, M.M.; McMahon, L.P.; Holt, S.G. Biological Variability of Plasma Intact and C-Terminal FGF23 Measurements. J. Clin. Endocrinol. Metab. 2012, 97, 3357–3365. [Google Scholar] [CrossRef]
- Levin, A.; Rigatto, C.; Barrett, B.; Madore, F.; Muirhead, N.; Holmes, D.; Clase, C.M.; Tang, M.; Djurdjev, O.; on behalf of the CanPREDDICT Investigators; et al. Biomarkers of Inflammation, Fibrosis, Cardiac Stretch and Injury Predict Death but Not Renal Replacement Therapy at 1 Year in a Canadian Chronic Kidney Disease Cohort. Nephrol. Dial. Transplant. 2014, 29, 1037–1047. [Google Scholar] [CrossRef]
- Christov, M.; Waikar, S.S.; Pereira, R.C.; Havasi, A.; Leaf, D.E.; Goltzman, D.; Pajevic, P.D.; Wolf, M.; Jüppner, H. Plasma FGF23 Levels Increase Rapidly after Acute Kidney Injury. Kidney Int. 2013, 84, 776–785. [Google Scholar] [CrossRef]
- Leaf, D.E.; Christov, M.; Jüppner, H.; Siew, E.; Ikizler, T.A.; Bian, A.; Chen, G.; Sabbisetti, V.S.; Bonventre, J.V.; Cai, X.; et al. Fibroblast Growth Factor 23 Levels Are Elevated and Associated with Severe Acute Kidney Injury and Death Following Cardiac Surgery. Kidney Int. 2016, 89, 939–948. [Google Scholar] [CrossRef]
- Neyra, J.A.; Moe, O.W.; Hu, M.C. Fibroblast Growth Factor 23 and Acute Kidney Injury. Pediatr. Nephrol. 2015, 30, 1909–1918. [Google Scholar] [CrossRef]
- Chang, H.-M.; Peng, K.-Y.; Chan, C.-K.; Sun, C.-Y.; Chen, Y.-Y.; Chang, H.-M.; Huang, C.-L.; Liu, P.-C.; Chen, P.-Y.; Wang, K.-C.; et al. FGF23 Ameliorates Ischemia-Reperfusion Induced Acute Kidney Injury via Modulation of Endothelial Progenitor Cells: Targeting SDF-1/CXCR4 Signaling. Cell Death Dis. 2021, 12, 409. [Google Scholar] [CrossRef]
- Singh, S.; Grabner, A.; Yanucil, C.; Schramm, K.; Czaya, B.; Krick, S.; Czaja, M.J.; Bartz, R.; Abraham, R.; Marco, G.S.D.; et al. Fibroblast Growth Factor 23 Directly Targets Hepatocytes to Promote Inflammation in Chronic Kidney Disease. Kidney Int. 2016, 90, 985–996. [Google Scholar] [CrossRef]
- Munoz Mendoza, J.; Isakova, T.; Ricardo, A.C.; Xie, H.; Navaneethan, S.D.; Anderson, A.H.; Bazzano, L.A.; Xie, D.; Kretzler, M.; Nessel, L.; et al. Fibroblast Growth Factor 23 and Inflammation in CKD. Clin. J. Am. Soc. Nephrol. 2012, 7, 1155. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.; Guo, K.; Xia, F.; Zhao, X.; Huang, Z.; Niu, J. FGF23C-Tail Improves Diabetic Nephropathy by Attenuating Renal Fibrosis and Inflammation. BMC Biotechnol. 2018, 18, 33. [Google Scholar] [CrossRef] [PubMed]
- Durlacher-Betzer, K.; Hassan, A.; Levi, R.; Axelrod, J.; Silver, J.; Naveh-Many, T. Interleukin-6 Contributes to the Increase in Fibroblast Growth Factor 23 Expression in Acute and Chronic Kidney Disease. Kidney Int. 2018, 94, 315–325. [Google Scholar] [CrossRef]
- Glosse, P.; Fajol, A.; Hirche, F.; Feger, M.; Voelkl, J.; Lang, F.; Stangl, G.I.; Föller, M. A High-Fat Diet Stimulates Fibroblast Growth Factor 23 Formation in Mice through TNFα Upregulation. Nutr. Diabetes 2018, 8, 36. [Google Scholar] [CrossRef]
- Yamazaki, M.; Kawai, M.; Miyagawa, K.; Ohata, Y.; Tachikawa, K.; Kinoshita, S.; Nishino, J.; Ozono, K.; Michigami, T. Interleukin-1-Induced Acute Bone Resorption Facilitates the Secretion of Fibroblast Growth Factor 23 into the Circulation. J. Bone Miner. Metab. 2015, 33, 342–354. [Google Scholar] [CrossRef]
- Chonchol, M.; Greene, T.; Zhang, Y.; Hoofnagle, A.N.; Cheung, A.K. Low Vitamin D and High Fibroblast Growth Factor 23 Serum Levels Associate with Infectious and Cardiac Deaths in the HEMO Study. J. Am. Soc. Nephrol. 2016, 27, 227. [Google Scholar] [CrossRef]
- Ishigami, J.; Taliercio, J.T.; Feldman, H.I.; Srivastava, A.; Townsend, R.R.; Cohen, D.L.; Horwitz, E.J.; Rao, P.; Charleston, J.; Fink, J.C.; et al. Fibroblast Growth Factor 23 and Risk of Hospitalization with Infection in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study. J. Am. Soc. Nephrol. 2020, 31, 1836. [Google Scholar] [CrossRef]
- Rossaint, J.; Oehmichen, J.; Van Aken, H.; Reuter, S.; Pavenstädt, H.J.; Meersch, M.; Unruh, M.; Zarbock, A. FGF23 Signaling Impairs Neutrophil Recruitment and Host Defense during CKD. J. Clin. Investig. 2016, 126, 962–974. [Google Scholar] [CrossRef]
- Hu, X.; Ma, X.; Luo, Y.; Xu, Y.; Xiong, Q.; Pan, X.; Xiao, Y.; Bao, Y.; Jia, W. Associations of Serum Fibroblast Growth Factor 23 Levels with Obesity and Visceral Fat Accumulation. Clin. Nutr. 2018, 37, 223–228. [Google Scholar] [CrossRef]
- Wojcik, M.; Janus, D.; Dolezal-Oltarzewska, K.; Drozdz, D.; Sztefko, K.; Starzyk, J.B. The Association of FGF23 Levels in Obese Adolescents with Insulin Sensitivity. J. Pediatr. Endocrinol. Metab. 2012, 25, 687–690. [Google Scholar] [CrossRef]
- Hanks, L.J.; Casazza, K.; Judd, S.E.; Jenny, N.S.; Gutiérrez, O.M. Associations of Fibroblast Growth Factor-23 with Markers of Inflammation, Insulin Resistance and Obesity in Adults. PLoS ONE 2015, 10, e0122885. [Google Scholar] [CrossRef]
- Rutkowski, J.M.; Pastor, J.; Sun, K.; Park, S.K.; Bobulescu, I.A.; Chen, C.T.; Moe, O.W.; Scherer, P.E. Adiponectin Alters Renal Calcium and Phosphate Excretion through Regulation of Klotho Expression. Kidney Int. 2017, 91, 324–337. [Google Scholar] [CrossRef]
- Tsuji, K.; Maeda, T.; Kawane, T.; Matsunuma, A.; Horiuchi, N. Leptin Stimulates Fibroblast Growth Factor 23 Expression in Bone and Suppresses Renal 1α,25-dihydroxyvitamin D3 Synthesis in Leptin-deficient Ob/Ob Mice. J. Bone Miner. Res. 2010, 25, 1711–1723. [Google Scholar] [CrossRef]
- White, K.E.; Evans, W.E.; O’Riordan, J.L.H.; Speer, M.C.; Econs, M.J.; Lorenz-Depiereux, B.; Grabowski, M.; Meitinger, T.; Strom, T.M. Autosomal Dominant Hypophosphataemic Rickets Is Associated with Mutations in FGF23. Nat. Genet. 2000, 26, 345–348. [Google Scholar] [CrossRef]
- Feng, J.Q.; Ward, L.M.; Liu, S.; Lu, Y.; Xie, Y.; Yuan, B.; Yu, X.; Rauch, F.; Davis, S.I.; Zhang, S.; et al. Loss of DMP1 Causes Rickets and Osteomalacia and Identifies a Role for Osteocytes in Mineral Metabolism. Nat. Genet. 2006, 38, 1310–1315. [Google Scholar] [CrossRef]
- Liu, S.; Guo, R.; Simpson, L.G.; Xiao, Z.-S.; Burnham, C.E.; Quarles, L.D. Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEX*. J. Biol. Chem. 2003, 278, 37419–37426. [Google Scholar] [CrossRef]
- Riminucci, M.; Collins, M.T.; Fedarko, N.S.; Cherman, N.; Corsi, A.; White, K.E.; Waguespack, S.; Gupta, A.; Hannon, T.; Econs, M.J.; et al. FGF-23 in Fibrous Dysplasia of Bone and Its Relationship to Renal Phosphate Wasting. J. Clin. Investig. 2003, 112, 683–692. [Google Scholar] [CrossRef]
- Avitan-Hersh, E.; Tatur, S.; Indelman, M.; Gepstein, V.; Shreter, R.; Hershkovitz, D.; Brick, R.; Bergman, R.; Tiosano, D. Postzygotic HRAS Mutation Causing Both Keratinocytic Epidermal Nevus and Thymoma and Associated With Bone Dysplasia and Hypophosphatemia Due to Elevated FGF23. J. Clin. Endocrinol. Metab. 2014, 99, E132–E136. [Google Scholar] [CrossRef]
- Shimada, T.; Mizutani, S.; Muto, T.; Yoneya, T.; Hino, R.; Takeda, S.; Takeuchi, Y.; Fujita, T.; Fukumoto, S.; Yamashita, T. Cloning and Characterization of FGF23 as a Causative Factor of Tumor-Induced Osteomalacia. Proc. Natl. Acad. Sci. USA 2001, 98, 6500–6505. [Google Scholar] [CrossRef]
- Shimizu, Y.; Tada, Y.; Yamauchi, M.; Okamoto, T.; Suzuki, H.; Ito, N.; Fukumoto, S.; Sugimoto, T.; Fujita, T. Hypophosphatemia Induced by Intravenous Administration of Saccharated Ferric Oxide: Another Form of FGF23-Related Hypophosphatemia. Bone 2009, 45, 814–816. [Google Scholar] [CrossRef]
- Kinoshita, Y.; Fukumoto, S. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment. Endocr. Rev. 2018, 39, 274–291. [Google Scholar] [CrossRef]
- Boyce, A.M.; Lee, A.E.; Roszko, K.L.; Gafni, R.I. Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management. Front. Endocrinol. 2020, 11, 293. [Google Scholar] [CrossRef]
- Fukumoto, S. FGF23 and Bone and Mineral Metabolism. In Bone Regulators and Osteoporosis Therapy; Stern, P.H., Ed.; Springer International Publishing: Cham, Switzerland, 2020; pp. 281–308. ISBN 978-3-030-57378-2. [Google Scholar]
- Schnedl, C.; Fahrleitner-Pammer, A.; Pietschmann, P.; Amrein, K. FGF23 in Acute and Chronic Illness. Dis. Markers 2015, 2015, 358086. [Google Scholar] [CrossRef]
- Reyes-Garcia, R.; Garcia-Martín, A.; García-Fontana, B.; Morales-Santana, S.; Rozas-Moreno, P.; Muñoz-Torres, M. FGF23 in Type 2 Diabetic Patients: Relationship with Bone Metabolism and Vascular Disease. Diabetes Care 2014, 37, e89–e90. [Google Scholar] [CrossRef]
- Rodelo-Haad, C.; Santamaria, R.; Muñoz-Castañeda, J.R.; Pendón-Ruiz de Mier, M.V.; Martin-Malo, A.; Rodriguez, M. FGF23, Biomarker or Target? Toxins 2019, 11, 175. [Google Scholar] [CrossRef]
- Rodríguez, M. FGF23: Is It Another Biomarker for Phosphate–Calcium Metabolism? Adv. Ther. 2020, 37, 73–79. [Google Scholar] [CrossRef]
- Linglart, A.; Biosse-Duplan, M.; Briot, K.; Chaussain, C.; Esterle, L.; Guillaume-Czitrom, S.; Kamenicky, P.; Nevoux, J.; Prié, D.; Rothenbuhler, A.; et al. Therapeutic Management of Hypophosphatemic Rickets from Infancy to Adulthood. Endocr. Connect. 2014, 3, R13–R30. [Google Scholar] [CrossRef]
- Felsenfeld, A.J.; Levine, B.S. Approach to Treatment of Hypophosphatemia. Am. J. Kidney Dis. 2012, 60, 655–661. [Google Scholar] [CrossRef]
- Shimada, T.; Fukumoto, S. FGF23 as a Novel Therapeutic Target. In Endocrine FGFs and Klothos; Kuro-o, M., Ed.; Advances in Experimental Medicine and Biology; Springer: New York, NY, USA, 2012; pp. 158–170. ISBN 978-1-4614-0887-1. [Google Scholar]
- Fukumoto, S. Targeting Fibroblast Growth Factor 23 Signaling with Antibodies and Inhibitors, Is There a Rationale? Front. Endocrinol. 2018, 9, 335401. [Google Scholar] [CrossRef]
- Moe, S.M.; Chertow, G.M.; Parfrey, P.S.; Kubo, Y.; Block, G.A.; Correa-Rotter, R.; Drüeke, T.B.; Herzog, C.A.; London, G.M.; Mahaffey, K.W.; et al. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. Circulation 2015, 132, 27–39. [Google Scholar] [CrossRef]
- Imel, E.A.; Glorieux, F.H.; Whyte, M.P.; Munns, C.F.; Ward, L.M.; Nilsson, O.; Simmons, J.H.; Padidela, R.; Namba, N.; Cheong, H.I.; et al. Burosumab versus Conventional Therapy in Children with X-Linked Hypophosphataemia: A Randomised, Active-Controlled, Open-Label, Phase 3 Trial. The Lancet 2019, 393, 2416–2427. [Google Scholar] [CrossRef]
- Linglart, A.; Imel, E.A.; Whyte, M.P.; Portale, A.A.; Högler, W.; Boot, A.M.; Padidela, R.; van’t Hoff, W.; Gottesman, G.S.; Chen, A.; et al. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia. J. Clin. Endocrinol. Metab. 2022, 107, 813–824. [Google Scholar] [CrossRef]
- Weber, T.J.; Imel, E.A.; Carpenter, T.O.; Peacock, M.; Portale, A.A.; Hetzer, J.; Merritt, J.L., II; Insogna, K. Long-Term Burosumab Administration Is Safe and Effective in Adults with X-Linked Hypophosphatemia. J. Clin. Endocrinol. Metab. 2023, 108, 155–165. [Google Scholar] [CrossRef]
- Jan de Beur, S.M.; Cimms, T.; Nixon, A.; Theodore-Oklota, C.; Luca, D.; Roberts, M.S.; Egan, S.; Graham, C.A.; Hribal, E.; Evans, C.J.; et al. Burosumab Improves Patient-Reported Outcomes in Adults with Tumor-Induced Osteomalacia: Mixed-Methods Analysis. J. Bone Miner. Res. 2023, 38, 1654–1664. [Google Scholar] [CrossRef]
- Fakhar, M.; Rashid, S. Targeted Inhibition of Klotho Binding to Fibroblast Growth Factor 23 Prevents Hypophosphetemia. J. Mol. Graph. Model. 2017, 75, 9–19. [Google Scholar] [CrossRef]
- Javle, M.; Roychowdhury, S.; Kelley, R.K.; Sadeghi, S.; Macarulla, T.; Weiss, K.H.; Waldschmidt, D.-T.; Goyal, L.; Borbath, I.; El-Khoueiry, A.; et al. Infigratinib (BGJ398) in Previously Treated Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements: Mature Results from a Multicentre, Open-Label, Single-Arm, Phase 2 Study. Lancet Gastroenterol. Hepatol. 2021, 6, 803–815. [Google Scholar] [CrossRef] [PubMed]
- Agoro, R.; Montagna, A.; Goetz, R.; Aligbe, O.; Singh, G.; Coe, L.M.; Mohammadi, M.; Rivella, S.; Sitara, D. Inhibition of Fibroblast Growth Factor 23 (FGF23) Signaling Rescues Renal Anemia. FASEB J. 2018, 32, 3752–3764. [Google Scholar] [CrossRef] [PubMed]
- Downs, R.P.; Xiao, Z.; Ikedionwu, M.O.; Cleveland, J.W.; Lin Chin, A.; Cafferty, A.E.; Darryl Quarles, L.; Carrick, J.D. Design and Development of FGF-23 Antagonists: Definition of the Pharmacophore and Initial Structure-Activity Relationships Probed by Synthetic Analogues. Bioorg. Med. Chem. 2021, 29, 115877. [Google Scholar] [CrossRef] [PubMed]
- Xiao, Z.; Liu, J.; Liu, S.-H.; Petridis, L.; Cai, C.; Cao, L.; Wang, G.; Chin, A.L.; Cleveland, J.W.; Ikedionwu, M.O.; et al. Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in Hyp Mice. Mol. Pharmacol. 2022, 101, 408–421. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Martínez-Heredia, L.; Canelo-Moreno, J.M.; García-Fontana, B.; Muñoz-Torres, M. Non-Classical Effects of FGF23: Molecular and Clinical Features. Int. J. Mol. Sci. 2024, 25, 4875. https://doi.org/10.3390/ijms25094875
Martínez-Heredia L, Canelo-Moreno JM, García-Fontana B, Muñoz-Torres M. Non-Classical Effects of FGF23: Molecular and Clinical Features. International Journal of Molecular Sciences. 2024; 25(9):4875. https://doi.org/10.3390/ijms25094875
Chicago/Turabian StyleMartínez-Heredia, Luis, Juan Manuel Canelo-Moreno, Beatriz García-Fontana, and Manuel Muñoz-Torres. 2024. "Non-Classical Effects of FGF23: Molecular and Clinical Features" International Journal of Molecular Sciences 25, no. 9: 4875. https://doi.org/10.3390/ijms25094875